Worldwide Bladder Cancer Market: Top Key Players are - AstraZeneca plc., Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Co., F. Hoffmann-La Roche

According to a recent study published by the Market Research Future analysts, the Global Bladder Cancer Market is growing at a moderate growth rate; mainly due to rise in the prevalence rate of the bladder cancer. Even though the exact cause of the bladder cancer is yet to be understood, there are certain factor that may increase the risk of developing a bladder cancer. These include adoption of unhealthy lifestyle, mutations in genetic profile of the patients and continuous exposure to harmful radiations are also responsible for the increase of the bladder cancer cases all across the world. Increasing government support, increased investment in the research and development, and rising awareness about the bladder cancer among masses also has contributed to the growth of the market. ssssOn the other hand, there are some obstacles in this market such as high cost of the treatment, expensive drugs, and side effects of the treatment. These all factors have negatively affected the widespread growth of overall bladder cancer market.

Get a sample report at https://www.marketresearchfuture.com/sample_request/1899 .

Key Players:

The global market consist of players such as Pfizer (US), Novartis AG (Switzerland), Oncogenex (US), Astellas (Japan), Eli Lilly and Company (US), AstraZeneca (UK), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline (UK), Accord Healthcare, Inc. (India), and Bristol-Myers Squibb company (US). These are some of the prominent players at the forefront of competition in the global bladder cancer market.

Global Bladder Cancer Market - Competitive Analysis

The market for bladder cancer is well established market with number of companies operating in this market. There are large number of companies involved in the development of the products including the drugs, molecules.

Bladder Cancer Market is becoming huge with increasing demand for the treatment options. Unavailability of absolute treatment has given a wide range of platform for the development of the market. Companies are focusing on the development of new products which will be cost effective and will have minimum side effects. Various companies are involved in the development of specific types of molecules, and novel therapies. These companies have adapted the strategies of the acquisitions, and also launching of the new products in order to strive in this big and competitive market. Moreover, competition amongst new market players is also expected to upsurge growth for bladder cancer drugs market over the next few years.

In October 2017, Astellas and Seattle Genetics initiated pivotal trial of Enfortumab Vedotin for patients with locally advanced or metastatic urothelial cancer.

In May 2017, AstraZeneca plc received US FDA accelerated approval for the drug Imfinzi (durvalumab) which is to be used for previously treated patients with advanced bladder cancer.

In February 2017, Bristol-Myers Squibb received FDA approval for Opdivo (nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.

In April 2017, FDA granted Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer. It is the first and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy.

In May 2017, Eli Lily & company announced results of their drug Cyramza’s phase III clinical trial for Bladder cancer. According to company, Some 531 patients with urothelial carcinoma were treated in the trial, with a statistically significant improvement in progression-free survival. With this, Company received huge boost for the development of this drug in the treatment of bladder cancer.

In May 2017, FDA granted BAVENCIO® (avelumab) approval for a common type of advanced bladder cancer.

Browse Complete Report at https://www.marketresearchfuture.com/reports/bladder-cancer-market-1899 .

The America region dominates the global bladder cancer market owing to the presence of huge patient population suffering from bladder cancer. According to American Cancer Society, in 2017, about 79,030 new cases of bladder cancer were found and about 16,870 deaths occurred due to bladder cancer only in United States and the number is projected to increase in the coming future. Moreover, certain factors such as changing lifestyle, and increasing government support, role of cancer care organisations in increasing awareness about the disease in people has also impacted on the growth of the bladder cancer market. Europe accounts for the second largest market for the bladder cancer, which is followed by Asia Pacific. Asia Pacific is the fastest growing market owing to the huge population base, increasing prevalence of bladder cancer, rapidly developing economies and presence of huge opportunity for the growth of the market. The Middle East & Africa has the least market share due to the unavailability of the required healthcare infrastructure, lack of awareness among people, and affordability issues due to presence of the poor economies in Africa region.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us

Market Research Future
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com

This release was published on openPR.